Could a diabetes drug help slow Parkinson's?
NCT ID NCT03439943
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 21 times
Summary
This phase 2 trial tested whether lixisenatide, a diabetes drug given as a daily injection, can slow the worsening of motor symptoms in people with early Parkinson's disease. 156 participants received either lixisenatide or a placebo for 12 months, alongside their usual Parkinson's medications. The study measured changes in movement ability to see if the drug has a disease-modifying effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU Toulouse
Toulouse, 31000, France
-
Creteil- Henri Mondor Hospital
Créteil, France
-
Pitié Salpêtrière Hospital
Paris, France
-
University Hospital of Amiens
Amiens, France
-
University Hospital of Besancon
Besançon, France
-
University Hospital of Bordeaux
Bordeaux, France
-
University Hospital of Caen
Caen, France
-
University Hospital of Clermont-Ferrand
Clermont-Ferrand, France
-
University Hospital of Lille
Lille, France
-
University Hospital of Limoges
Limoges, France
-
University Hospital of Lyon
Lyon, France
-
University Hospital of Marseille
Marseille, France
-
University Hospital of Montpellier
Montpellier, France
-
University Hospital of Nancy
Nancy, France
-
University Hospital of Nantes
Nantes, France
-
University Hospital of Nice
Nice, France
-
University Hospital of Poitiers
Poitiers, France
-
University Hospital of Rennes
Rennes, France
-
University Hospital of Rouen
Rouen, France
-
University Hospital of Strasbourg
Strasbourg, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lixisenatide (a daily injection drug)
What this could lead to
If it works, this could point toward a treatment that slows the worsening of movement problems in early Parkinson's disease.
What could go wrong
This is an early phase 2 trial with only 156 people, so results may not apply to everyone. The drug may cause side effects like nausea, and it is not yet proven to modify the disease long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.